Document 2836
 DOCN  M94A2836
 TI    Zidovudine or zidovudine/acyclovir in patients with asymptomatic HIV
       infection and CD4+ cell counts greater than 400/microL.
 DT    9412
 AU    Jahn S; Busch HW; Reichelt D; Christensen S; Zidek W; Department of
       Medicine, WWU Munster, Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):213 (abstract no. PB0280). Unique
       Identifier : AIDSLINE ICA10/94369739
 AB    OBJECTIVE: We have reported earlier that a combination therapy with
       zidovudine and acyclovir reduces the frequency of herpesvirus infections
       in patients with severe HIV-disease. 1. To determine the frequencies of
       herpesvirus infections (HSV, VZV, EBV) 2. The progression of clinical
       HIV-disease, development of AIDS or severe AIDS-related complex and 3.
       CD4+ cell count less than 350/microliters in patients with asymptomatic
       HIV-infection and CD4+ greater than 400/microliters in patients which
       received either AZT 500 mg/d or AZT 500/ACV 800 mg/d. METHODS: We
       analyzed the data of 165 patients over a period of 48 months. 85
       patients received AZT 500 mg/d and 80 patients received AZT 500 mg/ACV
       800 mg/d. Data were analyzed by survival methods, including Kaplan-Meier
       estimates and log-rank tests. RESULTS: Patients which received AZT
       500/ACV 800 mg/d developed significant less herpesvirus infections (HSV,
       VZV, EBV) than patients which received AZT 500 mg/d alone and showed
       significant more seldom a progression of clinical HIV-disease,
       development of AIDS or severe AIDS-related complex and a CD4+ cell count
       less than 350/mu. DISCUSSION AND CONCLUSIONS: Because of the reduction
       of herpesvirus infections (HSV, VZV, EBV), of disease progression and a
       CD4+ cell count less than 350/microliters it seems to be useful to offer
       all patients with asymptomatic HIV-infection and CD4+ cell counts
       greater than 400/microliters a combination therapy with AZT 500 mg/d and
       Acyclovir 800 mg/d.
 DE    Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL
       Acyclovir/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  AIDS-Related
       Opportunistic Infections/EPIDEMIOLOGY/PREVENTION &  CONTROL  Comparative
       Study  Drug Therapy, Combination  Herpesviridae
       Infections/EPIDEMIOLOGY/PREVENTION & CONTROL  Human  HIV
       Infections/*DRUG THERAPY/MORTALITY  Leukocyte Count  Life Tables
       Survival Analysis  Treatment Outcome  T4 Lymphocytes
       Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).